pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
nucresiran · news · pharmadog
← back to nucresiran
News mentioning nucresiran
10
stories
10d
Deep dive: Cardiovascular calamities and catalysts
biospace
Oct 20, 26
Alnylam bulls and bears fight it out after business-shaking guidance cut
biospace
Aug 31, 26
ESC ‘26: Cytokinetics’ sell-off, Arrowhead’s edge and a heart drug autopsy
biopharma dive
Aug 31, 26
ESC: Alnylam's next-gen silencer sees silver linings after fallout of AZ, Ionis trial in ATTR-CM
fiercebiotech
Aug 30, 26
STAT+: Alnylam defends heart disease drugs after failure of AstraZeneca’s Wainua
stat
Aug 28, 26
‘Worse than expected’ Wainua data muddies water for TTR silencers
biospace
Aug 28, 26
AstraZeneca, Ionis data spark debate about RNA drugs’ impact on deadly heart disease
biopharma dive
Aug 27, 26
What’s in Merck and Moderna’s cancer vaccine algorithm?
stat
Aug 3, 26
5 companies advancing ATTR assets in the wake of Wainua’s fail
biospace
Jul 31, 26
Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise
biospace